Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377208 | 0.98 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL7519633 | 0.98 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL4883420 | 0.98 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL81047 | 0.98 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL8379909 | 0.98 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL5267200 | 0.98 | NAAA (0.64) | NAAAEPHX1FAAHRAD52NPSR1 | |
| Hydrochloric Acid SCHEMBL5267197 | 0.96 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL394098 | 0.96 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL27285973 | 0.96 | NAAA (0.62) | NAAAEPHX1FAAHRAD52NPSR1 | |
| SCHEMBL168311 | 0.96 | NAAA (0.61) | NAAAEPHX1FAAHRAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134934-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | REGENX SCIENCE, INC. (US) | 2025-05-01 | — | — | US | claimed |
| US-20250134801-A1 | NOVEL METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX | REGENX SCIENCE, INC. (US) | 2025-05-01 | — | — | US | claimed |
| EP-4475859-A2 | NOVEL METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX | Regenx Science, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| EP-4475858-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | Regenx Science, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2023154876-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | REGENX SCIENCE, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| WO-2023154873-A2 | NOVEL METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX | REGENX SCIENCE, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20250134934-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | REGENX SCIENCE, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250134801-A1 | NOVEL METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX | REGENX SCIENCE, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4475859-A2 | NOVEL METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX | Regenx Science, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4475858-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | Regenx Science, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154873-A2 | NOVEL METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX | REGENX SCIENCE, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154876-A1 | IMPROVED METHODS FOR DECELLULARIZING EXTRACELLULAR MATRIX (ECM) AND PREPARING DECELLULARIZED ECM GELS AND USES THEREOF | REGENX SCIENCE, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20040091438-A1 | Polyorganosiloxane emulsions,process for producing the same and material for cosmetic preparation | DOW CORNING TORAY SILICONE CO. LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1394215-A1 | POLYORGANOSILOXANE EMULSION, PROCESS FOR PRODUCING THE SAME, AND MATERIAL FOR COSMETIC PREPARATION | Dow Corning Toray Silicone Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091438-A1 | Polyorganosiloxane emulsions,process for producing the same and material for cosmetic preparation | CUTA, UNG, PCNA | NAAA 327/4885EPHX1 1743/4885FAAH 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.